Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY

NCT03362502 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03362502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
January 23, 2018
Completion date
July 28, 2025
Enrollment
23 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy